Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Macular Degeneration × aflibercept × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neoplasm Metastasis 9 Colorectal Neoplasms 7 Rectal Neoplasms 5 Colorectal Cancer Metastatic 5 Ovarian Neoplasms 3 Neoplasms 3 Lung Neoplasms 3 Colonic Neoplasms 3 Uveal Melanoma 2 Melanoma 2 Fallopian Tube Neoplasms 2 Carcinoma, Ovarian Epithelial 2 Carcinoma, Non-Small-Cell Lung 2 Carcinoma 2 Urinary Bladder Neoplasms 1 Urethral Neoplasms 1 Stomach Neoplasms 1 Somatostatinoma 1 Small Cell Lung Carcinoma 1 Sarcoma 1 Prostatic Neoplasms 1 Pancreatic Neoplasms 1 Neurofibromatosis 2 1 Myeloproliferative Disorders 1 Multiple Endocrine Neoplasia Type 1 1 Macular Degeneration 1 Lung Diseases 1 Leukemia, Myelomonocytic, Chronic 1 Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1 Fibrolamellar hepatocellular carcinoma 1

Interventions

brolucizumab 1 aflibercept 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03710564 2023-01-30

MERLIN

Novartis

Phase 3 Terminated

535 enrolled 14 charts

Macular Degeneration, Neurofibromatosis 2

Data powered by HemOnc (CC BY 4.0) Colophon ⚡